Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68


From Clinical Trial Efficacy to Real-Life Effectiveness: Why Conventional Metrics do not Work.

Boissel JP, Cogny F, Marko N, Boissel FH.

Drugs Real World Outcomes. 2019 Sep;6(3):125-132. doi: 10.1007/s40801-019-0159-z.


Chronic Lung Allograft Dysfunction: A Systematic Review of Mechanisms.

Royer PJ, Olivera-Botello G, Koutsokera A, Aubert JD, Bernasconi E, Tissot A, Pison C, Nicod L, Boissel JP, Magnan A; SysCLAD consortium.

Transplantation. 2016 Sep;100(9):1803-14. doi: 10.1097/TP.0000000000001215. Review.


High Risk versus Proportional Benefit: Modelling Equitable Strategies in Cardiovascular Prevention.

Marchant I, Boissel JP, Nony P, Gueyffier F.

PLoS One. 2015 Nov 3;10(11):e0140793. doi: 10.1371/journal.pone.0140793. eCollection 2015.


Comparative transcriptomic analysis between an artificially induced SIRS in healthy individuals and spontaneous sepsis.

Monteiro Sousa C, Boissel JP, Gueyffier F, Olivera-Botello G.

C R Biol. 2015 Oct;338(10):635-42. doi: 10.1016/j.crvi.2015.05.001. Epub 2015 Aug 11.


An in silico target identification using Boolean network attractors: Avoiding pathological phenotypes.

Poret A, Boissel JP.

C R Biol. 2014 Dec;337(12):661-78. doi: 10.1016/j.crvi.2014.10.002. Epub 2014 Nov 11.


Comparison of an effect-model-law-based method versus traditional clinical practice guidelines for optimal treatment decision-making: application to statin treatment in the French population.

Kahoul R, Gueyffier F, Amsallem E, Haugh M, Marchant I, Boissel FH, Boissel JP.

J R Soc Interface. 2014 Nov 6;11(100):20140867. doi: 10.1098/rsif.2014.0867.


Better defining target populations for drugs with a view to reimbursement.

Massol J, Boissel JP.

Therapie. 2014 May-Jun;69(3):235-7. doi: 10.2515/therapie/2014027. Epub 2014 Jun 16.


Prediction of chronic lung allograft dysfunction: a systems medicine challenge.

Pison C, Magnan A, Botturi K, Sève M, Brouard S, Marsland BJ, Ernst F, Paprotka T, Deplanche K, Fritz A, Siroux V, Boissel JP, Corris PA, Auffray C, Nicod LP; SysCLAD consortium.

Eur Respir J. 2014 Mar;43(3):689-93. doi: 10.1183/09031936.00161313. No abstract available.


The public health benefit of medicines: how it has been assessed in France? The principles and results of five years' experience.

Maison P, Zanetti L, Solesse A, Bouvenot G, Massol J; ISPEP group of the French National Authority for Health.

Health Policy. 2013 Oct;112(3):273-84. doi: 10.1016/j.healthpol.2013.04.007. Epub 2013 May 10.


Is diabetes mellitus a heart disease equivalent in women? Results from an international study of postmenopausal women in the Raloxifene Use for the Heart (RUTH) Trial.

Daniels LB, Grady D, Mosca L, Collins P, Mitlak BH, Amewou-Atisso MG, Wenger NK, Barrett-Connor E; Raloxifene Use for the Heart (RUTH) Trial Investigators.

Circ Cardiovasc Qual Outcomes. 2013 Mar 1;6(2):164-70. doi: 10.1161/CIRCOUTCOMES.112.966986. Epub 2013 Mar 12.


Effect model law: an approach for the implementation of personalized medicine.

Boissel JP, Kahoul R, Marin D, Boissel FH.

J Pers Med. 2013 Aug 15;3(3):177-90. doi: 10.3390/jpm3030177. Review.


Guide de la Haute autorité de santé (HAS) : les études post-inscription sur les technologies de santé (médicaments, dispositifs médicaux et actes) : principes et méthodes.

Stamenkovic S, Solesse A, Zanetti L, Zagury P, Vray M; Le groupe « Intérêt de santé publique et études post-inscription » (ISPEP).

Therapie. 2012 Sep-Oct;67(5):409-21. doi: 10.2515/therapie/2012065. French.


La médecine personnalisée : comment passer du concept à l'intégration dans un plan de développement clinique en vue d'une AMM ?

Becquemont L, Bordet R, Cellier D; les participants à la table ronde N°3 de Giens XXVII.

Therapie. 2012 Jul-Aug;67(4):339-48. doi: 10.2515/therapie/2012050. French. No abstract available.


Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials.

Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, Kassai B, Moreau A, Gueyffier F, Cornu C.

PLoS Med. 2012;9(4):e1001204. doi: 10.1371/journal.pmed.1001204. Epub 2012 Apr 10.


Towards personalized medicine: exploring the consequences of the effect model-based approach.

Boissel JP, Kahoul R, Amsallem E, Gueyffier F, Haugh M, Boissel FH.

Per Med. 2011 Sep;8(5):581-586. doi: 10.2217/pme.11.54.


The global risk approach should be better applied in French hypertensive patients: a comparison between simulation and observation studies.

Marchant I, Nony P, Cucherat M, Boissel JP, Thomas SR, Bejan-Angoulvant T, Laugerotte A, Kahoul R, Gueyffier F.

PLoS One. 2011 Mar 3;6(3):e17508. doi: 10.1371/journal.pone.0017508.


How to best define target populations of medicines in view of their coverage by the national health insurance scheme?

Hamers FF, Massol J, Maillère P; participates of Round Table n° 5 Giens XXV.

Therapie. 2010 Jul-Aug;65(4):341-5, 335-9. doi: 10.2515/therapie/2010034. Epub 2010 Sep 21. English, French.


In silico study of the influence of intensity and duration of blood flow reduction on cell death through necrosis or apoptosis during acute ischemic stroke.

Chapuisat G, Dronne MA, Grenier E, Hommel M, Boissel JP.

Acta Biotheor. 2010 Sep;58(2-3):171-90. doi: 10.1007/s10441-010-9100-2. Epub 2010 Jul 28.


Définition des populations cibles des médicaments : comment anticiper au mieux la définition des populations cibles en vue du remboursement ?

Homers FF, Massol J, Maillère P; les participants à la Table Ronde n°5 de Giens XXV.

Therapie. 2010 Jul-Aug;65(4):335-9. doi: 10.2515/therapie/2010033. French. No abstract available.


SCORE should be preferred to Framingham to predict cardiovascular death in French population.

Marchant I, Boissel JP, Kassaï B, Bejan T, Massol J, Vidal C, Amsallem E, Naudin F, Galan P, Czernichow S, Nony P, Gueyffier F.

Eur J Cardiovasc Prev Rehabil. 2009 Oct;16(5):609-15. doi: 10.1097/HJR.0b013e32832da006.


Supplemental Content

Loading ...
Support Center